Volume 85, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



From September 2005 to March 2007, 238 individuals being vaccinated for the first time with the yellow fever (YF) -17DD vaccine were enrolled in a cohort established in Recife, Brazil. A prospective study indicated that, after immunization, anti-YF immunoglobulin M (IgM) and anti-YF IgG were present in 70.6% (IgM) and 98.3% (IgG) of the vaccinated subjects. All vaccinees developed protective immunity, which was detected by the plaque reduction neutralization test (PRNT) with a geometric mean titer of 892. Of the 238 individuals, 86.6% had IgG antibodies to dengue virus; however, the presence of anti-dengue IgG did not interfere significantly with the development of anti-YF neutralizing antibodies. In a separate retrospective study of individuals immunized with the 17DD vaccine, the PRNT values at 5 and 10 years post-vaccination remained positive but showed a significant decrease in neutralization titer (25% with PRNT titers < 100 after 5 years and 35% after 10 years).


Article metrics loading...

Loading full text...

Full text loading...



  1. Lindenbach BD, Thiel H-J, Rice CM, , 2007. Fields Virology. Philadelphia, PA: Quebecor Versailles, 11011133.
  2. Monath TP, , 2001. Yellow fever: an update. Lancet Infect Dis 1: 1120.[Crossref]
  3. Brasil. Ministério da Saúde 2009. Secretaria de Vigilância em Saúde. Guia de Vigilância Epidemiológia - Febre Amarela, Brasília, DF, Caderno 9. CID: 10 A:95, 19.
  4. Figueiredo LT, , 2007. Emergent arboviruses in Brazil. Rev Soc Bras Med Trop 40: 224229.[Crossref]
  5. Lourenco de Oliveira R, Vazeille M, de Filippis AM, Failloux AB, , 2003. Large genetic differentiation and low variation in vector competence for dengue and yellow fever viruses of Aedes albopictus from Brazil, the United States, and the Cayman Islands. Am J Trop Med Hyg 69: 105114.
  6. Lourenco-de-Oliveira R, Vazeille M, de Filippis AM, Failloux AB, , 2004. Aedes aegypti in Brazil: genetically differentiated populations with high susceptibility to dengue and yellow fever viruses. Trans R Soc Trop Med Hyg 98: 4354.[Crossref]
  7. Codeco CT, Luz PM, Struchiner CJ, , 2004. Risk assessment of yellow fever urbanization in Rio de Janeiro, Brazil. Trans R Soc Trop Med Hyg 98: 702710.[Crossref]
  8. Barrett AD, Teuwen DE, , 2009. Yellow fever vaccine—how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol 21: 308313.[Crossref]
  9. dos Santos CN, Post PR, Carvalho R, Ferreira II, Rice CM, Galler R, , 1995. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res 35: 3541.[Crossref]
  10. Galler R, Post PR, Santos CN, Ferreira II, , 1998. Genetic variability among yellow fever virus 17D substrains. Vaccine 16: 10241028.[Crossref]
  11. Pugachev KV, Guirakhoo F, Monath TP, , 2005. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 18: 387394.[Crossref]
  12. Arya SC, , 1999. Yellow fever vaccine. Emerg Infect Dis 5: 487489.[Crossref]
  13. Marchevsky RS, da Luz Leal M, Homma A, Coutinho ES, Camacho LA, Jabor AV, Galler R, Freire MS, , 2006. Molecular and phenotypic analysis of a working seed lot of yellow fever virus 17DD vaccine strain produced from the secondary seed lot 102/84 with an additional passage in chicken embryos. Biologicals 34: 191197.[Crossref]
  14. Suzano CE, Amaral E, Sato HK, Papaiordanou PM, , 2006. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24: 14211426.[Crossref]
  15. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, Monath TP, Rodigues SG, Laval C, Costa ZG, Vilela MF, Santos CL, Papaiordanou PM, Alves VA, Andrade LD, Sato HK, Rosa ES, Froguas GB, Lacava E, Almeida LM, Cruz AC, Rocco IM, Santos RT, Oliva OF, , 2001. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358: 9197.[Crossref]
  16. Silva ML, Espirito-Santo LR, Martins MA, Silveira-Lemos D, Peruhype-Magalhaes V, Caminha RC, de Andrade Maranhao-Filho P, Auxiliadora-Martins M, de Menezes Martins R, Galler R, da Silva Freire M, Marcovistz R, Homma A, Teuwen DE, Eloi-Santos SM, Andrade MC, Teixeira-Carvalho A, Martins-Filho OA, , 2010. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin Vaccine Immunol 17: 118126.[Crossref]
  17. Guimard T, Minjolle S, Polard E, Fily F, Zeller H, Michelet C, Tattevin P, , 2009. Short report: incidence of yellow fever vaccine-associated neurotropic disease. Am J Trop Med Hyg 81: 11411143.[Crossref]
  18. Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, Cetron MS, , 2001. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 7: 945951.[Crossref]
  19. Galler R, Pugachev KV, Santos CL, Ocran SW, Jabor AV, Rodrigues SG, Marchevsky RS, Freire MS, Almeida LF, Cruz AC, Yamamura AM, Rocco IM, da Rosa ES, Souza LT, Vasconcelos PF, Guirakhoo F, Monath TP, , 2001. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 290: 309319.[Crossref]
  20. Izurieta RO, Macaluso M, Watts DM, Tesh RB, Guerra B, Cruz LM, Galwankar S, Vermund SH, , 2009. Anamnestic immune response to dengue and decreased severity of yellow Fever. J Glob Infect Dis 1: 111116.[Crossref]
  21. Teixeira MG, Costa Mda C, Barreto F, Barreto ML, , 2009. Dengue: twenty-five years since reemergence in Brazil. Cad Saude Publica 25 (Suppl 1): S7S18.
  22. Kuno G, Gomez I, Gubler DJ, , 1987. Detecting artificial anti-dengue IgM immune complexes using an enzyme-linked immunosorbent assay. Am J Trop Med Hyg 36: 153159.
  23. Kuno G, Gomez I, Gubler DJ, , 1991. An ELISA procedure for the diagnosis of dengue infections. J Virol Methods 33: 101113.[Crossref]
  24. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N, , 1985. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22: 250254.
  25. Clark DH, Casals J, , 1958. Techniques for hemagglutination inhibition with arthropodborne viruses. Am J Trop Hyg 7: 561573.
  26. Reed LJMH, , 1938. A simple method of estimating fifty per cent endpoints. Am J Hyg 27: 493497.
  27. Marques ET, Jr Maciel Filho R, August PN, , 2008. Overcoming health inequity: potential benefits of a patient-centered open-source public health infostructure. Cad Saude Publica 24: 547557.[Crossref]
  28. Niedrig M, Kursteiner O, Herzog C, Sonnenberg K, , 2008. Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus. Clin Vaccine Immunol 15: 177181.[Crossref]
  29. Niedrig M, Sonnenberg K, Steinhagen K, Paweska JT, , 2007. Comparison of ELISA and immunoassays for measurement of IgG and IgM antibody to West Nile virus in human sera against virus neutralisation. J Virol Methods 139: 103105.[Crossref]
  30. Nogueira RM, Schatzmayr HG, Miagostovich MP, Cavalcanti SM, de Carvalho R, , 1992. Use of MAC-ELISA for evaluation of yellow fever vaccination. Rev Inst Med Trop Sao Paulo 34: 447450.[Crossref]
  31. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'Age-Stehr J, , 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56: 159167.[Crossref]
  32. Niedrig M, Lademann M, Emmerich P, Lafrenz M, , 1999. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 4: 867871.[Crossref]
  33. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR, , 1992. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14: 568579.[Crossref]
  34. Makela A, Nuorti JP, Peltola H, , 2002. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 110: 957963.[Crossref]
  35. Vazquez S, Valdes O, Pupo M, Delgado I, Alvarez M, Pelegrino JL, Guzman MG, , 2003. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. J Virol Methods 110: 179184.[Crossref]
  36. Monath TP, , 1971. Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol 93: 122129.[Crossref]
  37. Lhuillier M, Sarthou JL, Cordellier R, Monteny N, Gershy-Damet GM, Bouchite B, , 1986. Endemic emergence of yellow fever in the Ivory Coast: the place of anti-yellow fever IgM detection in the strategy of surveillance. Bull World Health Organ 64: 415420.
  38. Cordeiro MT, Schatzmayr HG, Nogueira RM, Oliveira VF, Melo WT, Carvalho EF, , 2007. Dengue and dengue hemorrhagic fever in the State of Pernambuco, 1995–2006. Rev Soc Bras Med Trop 40: 605611.[Crossref]
  39. Houghton-Trivino N, Montana D, Castellanos J, , 2008. Dengue-yellow fever sera cross-reactivity; challenges for diagnosis. Rev Salud Publica (Bogota) 10: 299307.[Crossref]
  40. Cordeiro MT, Silva AM, Brito CA, Nascimento EJ, Magalhaes MC, Guimaraes GF, Lucena-Silva N, de Carvalho EM, Marques ET, Jr, 2007. Characterization of a dengue patient cohort in Recife, Brazil. Am J Trop Med Hyg 77: 11281134.
  41. Braga C, Luna CF, Martelli CM, Souza WV, Cordeiro MT, Alexander N, Albuquerque MD, Junior JC, Marques ET, , 2010. Seroprevalence and risk factors for dengue infection in socio-economically distinct areas of Recife, Brazil. Acta Trop 113: 234240.[Crossref]
  42. Kuno G, , 2003. Serodiagnosis of flaviviral infections and vaccinations in humans. The flaviviruses: detection, diagnosis and vaccine development. Adv Virus Res 61: 365.[Crossref]
  43. Gómez SY, Ocazionez RE, , 2008. Anticuerpos Neutralizantes contra el Virus de la Fiebre Amarilla 17D en Colombianos Vacunados y no Vacunados con Inmunidad a Dengue. Rev Salud Publica (Bogota) 10: 796807.
  44. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, Bedford P, , 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66: 533541.
  45. Pfister M, Kursteiner O, Hilfiker H, Favre D, Durrer P, Ennaji A, L'Age-Stehr J, Kaufhold A, Herzog C, , 2005. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg 72: 339346.

Data & Media loading...

  • Received : 07 Sep 2010
  • Accepted : 27 Mar 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error